HIV infection is associated with a rapid and sustained inversion of the Vd1:Vd2 T-cell ratio in peripheral blood. Studies of antiretroviral therapy (ART)-treated cohorts suggest that ART is insufficient to reconstitute either the frequency or function of the cd T-cell subset. Recent advances are now beginning to shed light on the relationship between microbial translocation, chronic inflammation, immune ageing and cd T-cell immunology. Here, we review the impact of acute, chronic untreated and treated HIV infection on circulating and mucosal cd T-cell subsets and highlight novel approaches to harness cd T cells as components of anti-HIV immunotherapy.
INTRODUCTION
cd T cells are a subset of T cells that express a distinct T-cell receptor (TCR) consisting of a c and a d-chain. This allows cd T cells to respond rapidly to nonpeptide antigens without the requirement of MHC presentation. In humans, cd T cells have a relatively restricted repertoire of V gene segments and the most commonly used Vd gene segments are Vd1, Vd2 and Vd3. Human Vd1 T cells predominantly reside in tissue and can make up to 40% of the intraepithelial lymphocytes (IEL) in the gut epithelia.
1 Vd1 T cells are also distributed in other tissues including dermis, spleen and liver, where they are involved in sustaining homeostasis and maintaining epithelial tissue integrity. 2 Although Vd1 T cells are also present in peripheral blood, Vd2 T cells constitute the majority of human blood cd T cells 3 where they almost exclusively associate with the Vc9 chain. Unlike Vd1 T cells, which typically recognise CD1c and CD1d via the TCR, the Vc9Vd2 T cells recognise intermediate metabolites from the isoprenoid biosynthesis pathway, such as the host molecule isopentenyl pyrophosphate (IPP) or the pathogenassociated molecule (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP). [4] [5] [6] [7] [8] These phosphoantigens bind the protein BTN3A1, triggering an 'inside-out' conformational change that promotes BTN3A1 binding to the Vc9Vd2 TCR and subsequent T-cell activation. 9 Human Vd3 T cells have also been reported to recognise CD1d, but are usually only present in peripheral blood at low frequencies. 10 However, they have been observed to expand in the blood in patients with cytomegalovirus infection, CD4 T-cell deficiency and B-cell leukaemia.
were currently infected with the virus of which 1.8 million were children under the age of 15. Despite increasing awareness of the disease and improved access to antiretroviral therapy (ART), approximately 5000 individuals become newly infected every day. 16 In addition to infecting and depleting CD4 + T cells, HIV infection also has a wide overall effect on the immune system, mediated largely by the phenomenon of microbial translocation. 17 Rapid replication of HIV in gut-associated lymphoid tissue (GALT) results in substantial damage to the gut epithelial barrier and the subsequent translocation of microbial products such as LPS into the circulation. 18 This results in chronic immune activation and, consequently, dysfunction of conventional, bystander abT cells. Upregulation of HLA-DR and CD38 by T cells is associated with chronic immune activation and has proven to be strong predictors of disease progression. [19] [20] [21] [22] Additionally, markers such as PD-1, CD57 and CD100 have been used to define terminally differentiated, exhausted or dysfunctional T cells [23] [24] [25] [26] [27] and are now the target of immunotherapies aimed at reducing T-cell exhaustion. 28 While HIV is well known to impact the function and distribution of conventional T-cell subsets, the impact of the disease on cd T-cell subsets has been an ongoing subject of research since the late 1980s. 29 Multiple reports have since described an inversion of the typical Vd2:Vd1 T-cell ratio in the peripheral blood of HIV-infected/AIDS patients, [30] [31] [32] [33] which was quickly determined to represent an increase in Vd1 T-cell frequency 30, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] and a depletion of Vd2Vc9 T cells. [31] [32] [33] 35, 38, [41] [42] [43] [44] [45] [46] [47] [48] Subsequent investigations have focused on the mechanisms behind this expansion/depletion, as well as the relationship of cd T subsets to HIV disease progression. Here, we focus on reviewing the effect of HIV infection and antiretroviral therapy on Vd1 and Vd2 T-cell subsets, with a primary emphasis on observations obtained from human cohorts (summarised in Figure 1 ). Approaches to rescue and harness cd T-cell responses as a means of anti-HIV immunotherapy are discussed, as well as the future directions of this rapidly evolving field.
PROGRESSIVE HIV-1 INFECTION Peripheral Vd2Vc9 T cells
Loss of Vd2 T cells during untreated HIV disease correlates strongly with CD4 count and viral load and occurs quickly after infection. 46 Depletion preferentially affects Vd2 cells with a Vc9-Jc1.2 TCR rearrangement 49 associated with the major circulating phosphoantigen-reactive Vc9 + Vd2 + cell population. 50 Given early reports that Vd2 T cells lacked expression of CD4 51 and were resistant to direct HIV infection, 52 there has been a strong emphasis on determining the mechanism of peripheral depletion, albeit with little consensus. Li and Pauza presented evidence implicating the HIV gp120 binding proteins a4b7 and CCR5 in mediating Vd2 depletion in viremic patients. 53 gp120-induced cross-linking of CCR5 and a4b7 on CD4 À Vd2 T cells results in the activation of the p38 caspase pathway and eventual apoptosis, without productive infection of the cell. To date, this mechanism remains to be confirmed, but analysis of existing data from preclinical studies of a4b7 monoclonal antibody (mAb) blockade [54] [55] [56] may provide interesting insights into this phenomenon. An alternative hypothesis suggests that microbial translocation associated with acute HIV infection could drive Vd2 T-cell activation and apoptosis. Analysis of a cohort of 79 acutely infected men suggested, however, that there is no relationship between biomarkers of microbial translocation and Vd2 frequency. 32 While two studies have reported a correlation between microbial translocation and bulk cd T-cell activation, it is unclear whether this relationship reflects activation of the Vd1 or Vd2 population, or simply the change in Vd1:Vd2 ratio. 32, 33 Vd2 depletion is also associated with a reduction of antigen-induced IFNc and proliferative/cytotoxic capacity 48, 58, 59 in the residual Vd2 population. Changes in Vd2 cytokine production may be related in part to the relative expansion of terminally differentiated memory (T EMRA ) cells and loss of the central memory (T CM ) subset during chronic infection. 32, 33, 47 Although all Vd2 memory subsets exhibit significant increases in activation during acute and chronic HIV infection, 33, 47 T EMRA cells tend to exhibit the highest levels of activation as measured by CD38 expression. 33 However, no studies have conclusively demonstrated a causal relationship between memory differentiation or activation and loss of antigen-induced cytokine responses in HIV.
Interesting data regarding the relationship between HIV viremia and Vd2 T cells come from a study of structured treatment interruption (STI), where participants receiving antiretroviral therapy (ART) ceased treatment for 4-6 weeks. Within the first month following viral rebound, the Vd2 compartment lost nearly all capacity for IFNc production in response to antigen stimulation.
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While slower, Vd2 T-cell counts and the frequency of TCM cells both declined by the end of the STI. All perturbations in the Vd2 population were restored within a month of resumption of ART, demonstrating the rapid and reversible nature of the Vd2 response to viremia.
Although a mechanistic explanation of this relationship is still lacking, it is possible that Vd2 T-cell anergy is induced by productive HIV infection of DCs, which can inhibit Vd2 responses to phosphoantigen in vitro 61 in a contact-dependent manner. 62 
Peripheral Vd1 T cells
The destructive impact of HIV infection on Vd2 T cells stands in direct contrast to the observed expansion of peripheral Vd1 T cells, 32, [36] [37] [38] which occurs rapidly during acute infection (and prior to HIV seroconversion 38 ). Several studies have confirmed that the relative enrichment of Vd1 cells as a proportion of the total cd T-cell population is also reflected as an increase in absolute Vd1 33, 38 (or Vd2-
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) T-cell count in the periphery. Similar to Vd2 cells, Vd1 cells are significantly more activated in HIV-infected subjects compared with controls. 37, 40, 47 In acute, chronic and naturally controlled infection, the majority of Vd1 cells exhibit a T EMRA phenotype, 37, 40, 41, 44 which correlates with absolute Vd1 T-cell counts 47 and is suggestive of antigen-driven proliferation and activation. 41 However, observations that Vd1 T-cell frequency is increased even in elite or viremic controllers (with low or undetectable viral loads) 40, 44 suggest that HIV replication itself does not drive this expansion. Rather, Vd1 expansion may be linked to microbial translocation, as nonhuman primate models have shown a correlation between lymph node Eschericia coli levels and peripheral Vd1 frequency. 63 Another potential mechanism for the accumulation of peripheral Vd1 cells lies in the ability of Tat peptides to block Vd1 chemotaxis, 36 which may reduce Vd1 cell recruitment from the periphery to mucosal sites, a phenomenon which is supported by some evidence from nonhuman primates (NHPs). 64 Notably, however, evidence exists for the simultaneous accumulation of Vd1 cells in both the periphery and gut mucosa in humans, 38, 65 63 Differences in antigen reactivity and IL-17 production may be related to the duration of stimulation and cell culture, particularly in the case of Candida, but will need to be resolved in future studies.
In addition to cytokine production, clinically relevant characteristics of Vd1 cells include the expression of NK cell receptors (NKR) and the capacity to mediate cellular cytotoxicity of HIVinfected target and bystander cells. 43, 67 Assessment of NKG2A and NKG2C expression, which initiates inhibitory or activating signals in response to HLA-E binding, respectively, demonstrated that Vd1 cells from HIV-infected subjects progressively lose NKG2A expression and acquire NKG2C. 43 In vitro, these NKG2C + Vd1 cells can recognise and kill HIV-infected CD4 + T cells. 43 The 68 possibly due to HLA-E presentation of a capsid-derived peptide that blocks NKG2A inhibitory signalling. 69 Conversely, elevation of HLA-A, and subsequently HLA-E, expression during infection is associated with poor immunological control of HIV, which is speculated to occur due to NKG2A-mediated inhibition of NK cell function. 70 Blockade of NKG2A in vitro suggests that Vd1 cells, unlike NK cells, might be relatively resistant to NKG2A-mediated inhibitory signalling. 43 The role for CD94/NKG2A + Vd1 cells to control HIV replication or to be inhibited by HLA-E expression during disease therefore remains to be determined.
Mucosal cd T-cell subsets
While studies of peripheral blood samples provide important insights into cd T-cell biology, Vd1 cells are naturally enriched in the same mucosal tissues that support HIV replication (i.e. the gut mucosa 38, 41 and female reproductive tract This was confirmed by a detailed study from Poles and colleagues, who compared Vd1 and Vd2 subset frequencies in the peripheral blood and rectal mucosa of healthy and HIV-infected participants.
38 cd T-cell dynamics in the gut reflected those of the peripheral blood, with significant increases in Vd1 and decreases in Vd2 frequency during infection. Despite the parallel dynamics of the cd T-cell populations at these two site, analysis of CDR3 length showed little overlap between the two anatomical sites for either Vd1 or Vd2 subsets, as well as evidence of private, polyclonal expansions. 38 In contrast to these results, a study of 15 acutely and 14 chronically infected participants found a significant loss of Vd1 cells in the duodenum during chronic infection, with no change in Vd2 frequency. 41 Duodenal Vd1 cells of chronically-infected participants exhibited an increase in T EMRA differentiation compared with controls, although mucosal Vd1 cells were predominately T EM phenotype, which is distinct from the peripheral blood. Beyond differences in anatomical sampling location (duodenum versus rectum), there are limited data available to explain the discrepancies in these studies.
To date, only one study has assessed the impact of HIV infection on cd T cells at the female reproductive tract and involved mostly participants receiving ART. In this group, HIV infection was associated with a significant reduction in both Vd1 and Vd2 frequencies at the endocervix, 42 but memory distribution, NKR expression or function was not assessed.
IMPACT OF ART ON cd T-CELL POPULATIONS Vd2 T cells
Numerous studies have assessed Vd1 and Vd2 Tcell frequencies in ART-treated cohorts, although substantially fewer have provided more comprehensive data regarding phenotype and function. Both cross-sectional and longitudinal cohort studies find that ART fails to restore normal frequencies or numbers of Vd2 T cells. 32, 33, 38, [71] [72] [73] This observation is corroborated by evidence that ART only partially restores the depletion of Jc1.2 TCR repertoire, with almost no subjects exhibiting a typical frequency of Jc1.2 chains within the Vd2 subset 49, [73] [74] [75] and few intraparticipant changes in a longitudinal study. 76 Phenotypically, more studies report residual activation of the Vd2 subset during ART compared with healthy controls 33, 71 than normalisation of activation. 47 Data on memory subset distribution is more controversial, with some evidence that the expanded TEMRA population persists during ART, 71, 73 while other studies show a reduction in TEMRA frequencies that closely resemble uninfected controls. 32, 33, 47 Functionally, the majority of evidence suggests that Vd2 cytokine production, 47, 57, 71, 72 GzmB expression/ cytotoxicity 73 and proliferative capacity 75 remain compromised during ART, with only a single study showing a beneficial impact of ART on Vd2 proliferation and TNFa secretion.
59

Vd1 T cells
Cross-sectional data support the maintenance of an expanded Vd1 cell population during viral suppression, 32, 33, 38, 40, 47, 57, 71 an observation that was also confirmed in the longitudinal follow-up of 8 subjects from the day of ART initiation through day 540 on therapy. 38 At mucosal sites, the population of expanded cd T cells is maintained during ART, 77 with only modest normalisation in some individuals. 38 The peripheral Vd1 subset in ART cohorts retains the T EMRA phenotype associated with untreated infection 40, 47 and is reported to express elevated levels of PD-1 compared with healthy controls. 71 Whether ART reduces Vd1 activation is unresolved, 47, 71 but evidence suggests ongoing Vd1 proliferation during viral suppression 47 and the maintenance of a large proinflammatory IFNc + TNFa + MIP-1b+ polyfunctional population. 40 A single study of NKR expression reported elevated levels of CD94/ NKG2A, CD158a, CD158b and NKB1 on Vd1 cells compared with healthy controls, 78 which was accompanied by a loss of CD28 expression and an upregulation of CD45RO. 78 
MICROBIAL TRANSLOCATION, IMMUNE ACTIVATION AND APOPTOSIS
The relationship between microbial translocation, systemic immune activation and perturbations of cd T-cell subsets has been a common and enduring thread throughout the studies described above. Microbial translocation occurs as a result of the massive depletion of CD4 + T cells at the gut mucosa during acute HIV or SIV infection. 79, 80 This includes the preferential loss of Th17 cells, 81 which contribute to the maintenance of epithelial barrier integrity and wound healing in the gastrointestinal mucosa. The dysregulation of mucosal immunity and loss of epithelial integrity allow the translocation of microbial products such as LPS into the circulation, resulting in systemic immune activation and inflammation 17 (recently reviewed in References 80 and 82). Unfortunately, suppressive ART is unable to fully restore the mucosal CD4 + T-cell compartment and abolish systemic inflammation. 80 The disruption of mucosal immunity not only allows microbial products to translocate into the circulation, but also alters the composition of the gut microbiota. A number of human cohort studies have consistently shown an enrichment of proinflammatory bacteria such as the Enterobacteriaceae family and a loss of clades such as Bacteriodes. 80 Enterobacteriaceae are particularly likely to translocate across the mucosal barrier and induce the production of reactive oxygen species by innate immune cells, driving inflammation. At least one member of this family, E. coli, activates Vd2 T cells in vitro, raising the possibility that sustained exposure to translocated microbes could drive apoptosis of cd T cells, similar to the apoptosis of bystander CD4 + in the lamina propria that occurs by Fas-FasL interactions. 79 While the impact of microbiome perturbations on the gut-resident Vd1 T-cell population remains to be understood, data have shown a correlation between iNKT cells in the gut mucosa and the prevalence of Bacteroides and Prevotella microbes. 83 Thus, cd T cells may be directly impacted by changes in the microbial community at the gut mucosa, the translocation of proinflammatory products into the circulation, or dysregulation of innate and adaptive immune cells during both untreated and treated HIV infection. Although HIV elite/viral controllers exhibit Vd2 depletion relative to healthy controls, they maintain Vd2 frequencies that are significantly higher than either untreated or ART-treated subjects. 44, 87 These cells predominately exhibit a T CM phenotype 87 and produce more IL-17 than cells from viremic patients. 44 Unfortunately, such studies are confounded by an inability to determine whether viral control preserves cd T-cell ratios and phenotypes, or whether maintenance of a T CM /IL-17-expressing Vd2 population contributes to the control of viral replication. Nonhuman primates offer a unique opportunity to longitudinally compare preinfection cd populations to infection susceptibility and viral load setpoint. Although Tuero et al. 88 reported an inverse correlation between endocervical Vd2 Tcell frequency and chronic viral load (VL) in SIVinfected macaques, supporting a potential protective role for cd T cells in this animal model, these studies are still lacking in the literature and this should be further investigated in future studies. 89 and dysfunction. 90 At the site of TB infection, however, it is unclear what impact HIV has on lung cd T-cell populations. Only a single study has reported BAL cd T-cell numbers in healthy and HIV-infected participants where there was a significant increase in total cd cells during HIV infection, but the delta chain usage was not determined. 91 However, the possible impact of HIV infection on Vd2 responses to Mycobacterium has been clearly demonstrated in NHP models. Na€ ıve macaques are able to induce robust primary and recall Vd2 responses to BCG vaccination in the periphery and lung, while SIV-infected macaques showed no response to BCG in either site. 92 These cells are suggested to participate in the control of CMV replication and display potent anti-CMV responses in vitro. 12 Although the expansion of Vd1 cells as a result of HIV infection would presumably be beneficial for control of CMV infection, CMV replication is enhanced by inflammatory stimuli. Since it is reported that the functional characteristics of the expanded Vd1 cells in HIV + individuals are skewed towards a proinflammatory profile, this may instead contribute to CMV-associated morbidity, although this remains to be determined.
CLINICAL IMPACT OF cd T-CELL PERTURBATIONS DURING HIV INFECTION
Impact on coinfection
While suppressive ART successfully controls HIV replication regardless of cd T-cell reconstitution, residual impairment of the Vd2 subset likely has profound implications for immunity against a number HIV coinfections. Tuberculosis is currently the leading cause of death among HIV-infected individuals, and evidence suggests that active TB and HIV infection have additive effects on peripheral Vd2 depletion
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Furthermore, it is unclear whether the high prevalence of CMV infection among HIV + individuals is a driver of the Vd1 T-cell expansion observed during chronic infection.
Human herpesvirus 8 (HHV8) is also a virus which has increased seroprevalence in HIVinfected individuals and can cause significant disease in the form of Kaposi's sarcoma (KS). 100 Although the effector populations involved in control of this virus remain elusive, HHV8 infection is also associated with an expansion of Vd1 cells that respond to HHV8-infected cells and prevent virus release in immunocompetent hosts. 101 The role cd T cells play in promoting HHV-8 to progress to KS is currently unknown, but considering that inflammatory cytokines including IFN-c, IL-6, IL-1b and TNF-a are produced by infiltrating cells in lesions of KS, expanded Vd1 cells in HIV + individuals may potentially contribute to progression of clinical symptoms in a similar way as with CMV. 102 Other common coinfections among HIV-infected populations include Cryptococcus, viral hepatitis and malaria. There are little data available regarding cd T-cell responses to Cryptococcus infection in HIV-infected human cohorts, but murine studies have established a role for cd T cells in Cryptococcal immunity in the lung. 103, 104 Hepatitis B and C infections have a deleterious impact on cd T cells, similar to HIV infection, which is discussed more fully below. Studies in malaria-endemic populations have revealed a substantial role for cd T cells in immunity to Plasmodium spp. This topic has been recently reviewed in References 105 and 106, which highlight the protective and immunoregulatory roles of both Vd2 and Vd1 cd subsets. Surprisingly, however, there are no studies of HIV/malaria coinfection that report on cd T cells, which would represent an interesting focus for future clinical cohorts.
Impact on immune cell crosstalk
cd T cells can not only exert direct antimicrobial activity, but can also orchestrate and regulate the activation, maturation and recruitment of a variety of other immune cells. 107, 108 Activated Vd2 cells from healthy individuals can induce the maturation of neutrophils, 109 DCs and B cells into APCs. 110 Some evidence that this function is compromised during HIV infection, as HIV-infected APCs cannot undergo full cd T cellinduced maturation in vitro, leading to highresidual CCR5 expression and low CD86 and HLA-DR expression. 62 This impairment of crosstalk may enhance DC susceptibility to infection through CCR5 expression, as well as compromise CD4 + T-cell responses that rely on DC-mediated antigen presentation. To date, however, followup on these observations is lacking. Additionally, Vd2 cells can themselves present antigen and act as APCs for conventional ab T cells. 111 Antigenactivated Vd2 cells express HLA-DR, CD80, CD86, CD40 and CD54 at levels comparable to LPSmatured DCs and can induce primary ab T-cell responses.
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Transient activation-induced upregulation of CCR7 implies that Vd2 may home to draining lymph nodes during infection initiate adaptive immune responses. Considering the residual depletion, terminal differentiation and dysfunction that characterise Vd2 cells in ARTtreated subjects, it is likely that acquisition of APC function following antigen stimulation is compromised in the context of HIV infection. The contribution of such dysfunction to poor antimicrobial immunity or vaccination in ARTtreated subjects should be further explored, as in vivo Vd2 immunotherapy could be considered to address these defects in immune function.
More recently, Vd2 cells have been recognised to provide CD40L-dependent help to B cells. [112] [113] [114] [115] [116] As noted above, the transient expression of CCR7 after activation allows Vd2 cells to traffic to secondary lymphoid tissues, where they cluster within the germinal centre of mucosal B-cell follicles. 116 Stimulation with the phosphoantigen IPP is sufficient to elicit the delayed but robust expression of surface molecules involved in B-cell help; 36-84 h poststimulation, Vd2 T cells express CD40L, ICOS, OX-40 and CD70. 116 In vitro coculture assays indicate that activated Vd2 cells can promote B-cell antibody secretion to a similar, or even increased, degree as T FH cells. 116 Further studies have suggested that antigen exposure in the presence of IL-21 is required to induce the expression of CD40L and ICOS on circulating Vd2 cells. 113, 114 Interestingly, treatment of macaques with intravenous HMBPP and IL-2 during chronic SHIV infection resulted a prolonged boosting of SHIVenv-specific antibody titres, suggesting that Vd2 cells can contribute to humoral immunity in vivo. Despite these fascinating observations, further data regarding the impact of Vd2 depletion on humoral immunity during HIV infection are lacking.
cd T CELLS IN ANTI-HIV IMMUNOTHERAPY
Interest is increasing in developing host-directed immunotherapies to either supplement or replace current ART. Studies which have investigated the use of Vd2 cells for anti-HIV immunotherapy are summarised in Table 1 118 These responses are largely maintained, if not slightly enhanced, in ART-treated subjects, suggesting that Vd2 cells derived from HIV-infected individuals could contribute to the killing of HIVinfected target cells. 118 More encouragingly, ex vivo expansion of Vd2 cells from HIV-infected subjects results in an upregulation of CD16 expression and quantifiable ADCC of antibodycoated targets. 119 Any immunotherapy-based intervention using autologous Vd2 cells will require in vitro expansion to generate sufficiently large numbers of cells for reinfusion. Ex vivo antigen-driven Vd2 T-cell expansion appears to be a viable and reproducible strategy for the production of large numbers of autologous Vd2 cells from ART-treated HIV-infected individuals, although optimal expansion culture conditions may differ between healthy and infected groups. 120 Expanded cells express low levels of inhibitory surface receptors and can kill latently infected CD4 + T cells after latency reversal with vorinostat in vitro. 120 In vivo, however, results of cd T-cell immunotherapy are varied. Administration of HMBPP and IL-2 to chronically SIV-infected macaques expanded and activated Vd2 T cells, transiently boosted SHIVspecific CD8 + T-cell responses and resulted in a sustained increase of SHIV-specific antibody titres. 121 Nonetheless, there was no impact of Vd2 expansion on viral load or disease progression during chronic infection, and a negative impact of Vd2 expansion during acute infection. These results were mirrored in a study of humanised mice treated with expanded Vd2 cells, which similarly observed no protective effect of Vd2 treatment on viral replication or CD4 + T-cell depletion. 122 
SIMILARITIES WITH OTHER CHRONIC INFLAMMATORY DISEASES
The hallmark impacts of HIV infection on cd T cells (Vd2:Vd1 ratio inversion, activation and terminal differentiation, functional defects) are, in fact, not unique to HIV infection itself. Other chronic inflammatory diseases are associated with similar effects, including kidney disease, viral hepatitis and obesity.
Understanding the commonalities in pathogenesis between these diverse conditions may provide further insight into the mechanisms of cd perturbation and identify useful therapeutic targets.
Chronic kidney disease (CKD) is a progressive condition in which the loss of renal function results in the accumulation of uraemic toxins and proinflammatory cytokines (reviewed in Reference 123). End-stage renal disease (ESRD), the final stage of CKD, is associated with high levels of immune activation, poor responses to immunisation and high susceptibility to infection. Matsumoto first reported a significant loss of cd T cells among CKD patients requiring hemodialysis. 124 They speculated that cd depletion likely occurred because of Fas-and LFA-1-dependent apoptosis related to uraemia. Similarly, we observed a significant loss of phosphoantigenreactive cd T cells in ESRD patients compared with healthy controls.
125 Surprisingly, however, there was no relationship between plasma proinflammatory cytokine levels and cd frequency or dysfunction, 125 raising the question of what drives cd T-cell loss during ESRD. Similar to HIV infection, it is unclear whether low peripheral cd frequencies truly reflect apoptosis or, instead, recruitment to inflamed tissues. cd frequencies only partially normalise following kidney transplantation, with Vd2 frequencies remaining significantly lower than healthy controls. 126 The fact that uraemia-associated changes in the cd repertoire are not effectively reversed upon transplantation suggests that transplant patients may exhibit long-term susceptibility to some infections, similar to HIV ART-treated patients.
Viral hepatitis is also associated with changes in the circulating cd repertoire that are highly reminiscent of HIV infection. Chronic HCV infection is associated with peripheral Vd2 depletion, 127, 128 acquisition of an activated/T EMRA phenotype, 128, 129 upregulation of CD16 and granzyme 129 and functional impairment. 128, 129 HBV-infected subjects exhibit loss of peripheral Vd2 cells 130, 131 and/or expansion of peripheral Vd1 cells, 132 which correlates with serum ALT levels. 130, 131 Residual Vd2 cells from these individuals are impaired for IFNc production, cytotoxicity 130 and proliferation 131 and exhibit an activated, TEMRA surface phenotype. 131 Expression of granzyme and cytotoxic markers is particularly enhanced in HCV-infected subjects with greater degrees of liver damage, suggesting the potential involvement of cd T cells in mediating immunopathology during infection. Despite this, phosphoantigen-activated Vd2 cells can restrict in vitro HCV replication in an IFNcdependent manner, 133 making them potential immunotherapeutic targets for HCV treatment. In vitro studies suggested that Vd2 dysfunction may be at least partially abrogated by treatment with IFNa, which boosts phosphoantigen responses in cd T cells from both healthy and HCV-infected subjects 128 (although this effect was not replicated by others 129 ). In vivo, however, a standard course of Peg-IFNa and ribavirin therapy resulted in pronounced Vd2 anergy after 4 weeks of treatment in two studies of chronically HCVinfected patients. 129, 134 Notably, although Vd2 IFNc responses were decreased/almost absent after treatment, perforin and degranulation responses were elevated, suggesting the possibility that IFNa drives a transition of Vd2 cells away from cytokine responses and towards cytotoxicity. 129 The results of these clinical trials highlight important considerations for the in vivo use of drugs to promote Vd2 activation and proliferation during treated HIV infection, and the need to assess anergy at multiple timepoints after therapy.
Similar to CKD patients, obese adults exhibit increased susceptibility to infection associated with chronic inflammation. 135, 136 Peripheral Vd2 T cells are depleted in obese individuals (in a BMIdependent manner), 137, 138 are more likely to exhibit a T EMRA phenotype and respond poorly to influenza-infected APCs, 138 mirroring the effects of HIV infection, HBV/HCV infection and renal disease on this compartment. As expected, cytokine supplementation overcomes some of the Vd2 function defect, with IL-2 boosting in vitro Vd2 function among obese subjects. 138 Interestingly, these three conditions, as well as HIV infection, all involve some degree of gut dysbiosis. As previously discussed, HIV infection results in substantial damage to the gut epithelium and microbial translocation, which causes widespread immune activation. 139 Microbial translocation has also been reported in ESRD/CKD cohorts [140] [141] [142] and is increasingly being recognised as an important driver of T-cell dysfunction and chronic inflammation. 143, 144 Indeed, we found that plasma sCD14 levels in ESRD patients correlate with HMBPP-induced IFNg production by cd T cells, suggesting a possible link between microbial translocation and Vd2 T-cell function. 125 Similar observations have been made in the context of chronic HCV/HBV infection and liver cirrhosis, where overgrowth of pathogenic gut bacteria increases gut permeability and allows translocation of bacterial products into the liver via the portal vein. 139, 145, 146 Finally, obese individuals also exhibit elevated levels of LPS and other markers of microbial translocation, supporting a putative link between gut permeability, low-grade inflammation, and cd Tcell depletion and dysfunction. 147, 148 
UNRESOLVED QUESTIONS AND FUTURE DIRECTIONS
As the field of HIV immunology moves forward from studies of HIV pathogenesis towards a focus on inflammation and immune ageing among ARTtreated populations, 149 there are several key questions surrounding cd T-cell immunology that remain unanswered. First, the link between poor reconstitution of the cd compartment and persistent innate immune activation and inflammation during ART is poorly understood. In a fascinating study, Belkina et al. comprehensively assessed the expression of inhibitory surface receptors on a wide range of lymphocyte subsets including two NK cell populations, conventional T cells, Tregs, iNKT cells and cdT cells in ART-treated and control participants. 150 Importantly, these cohorts were stratified for age, allowing for a simultaneous assessment of immune ageing in each group. Among all lymphocyte subsets, only cd phenotype was sufficient to distinguish between the control and infected groups. A transition of the cd compartment from 'resting' CD160 + phenotype to an 'activated/exhausted' TIGIT + PD-1+ phenotype was associated with plasma-derived proinflammatory profile. 150 While an inversion of the Vd2:Vd1 ratio was confirmed for a subset of HIV-infected study participants, no data were available to assess the separate contribution of Vd1 and Vd2 cells to the HIVassociated inflammation and ageing. Such information will be critical to understanding which cd subset primarily expressed the TIGIT + PD-1+ phenotype and/or correlates mostly strongly with plasma inflammatory biomarkers. In addition to these data, a transcriptomics study of mitogen-activated lymphocyte responses identified cd T-cell differentiation as a differentially regulated pathway between healthy control and long-term ART cohorts. 149 Second, the field will benefit from a better understanding of the composition of the expanded Vd1 subset in ART cohorts. Vd1 T cells include CD1-restricted, lipid-reactive T cells, as well as cells with undefined antigen specificity and numerous mechanisms to sense host cell stress. As studies undertake novel approaches to defining Vd1 T-cell subsets with different functions and phenotypes, 151 we will move closer to understanding what drives the dramatic peripheral expansion and proinflammatory cytokine profile of these cells. It is interesting to note that the phenomena of microbial translocation and gut dysbiosis are common to many chronic inflammatory diseases associated with changes in the Vd1:Vd2 T-cell ratio. Recent data from murine models highlight the physiological importance of gut-derived cd cells and their ability to traffic to inflamed tissues, including the brain. 152 Whether gut dysbiosis is a predominate driver of cd dysfunction and accumulation during HIV or other viral infections remains to be fully investigated.
Finally, the question of whether productive HIV infection of Vd2 T cells occurs in vivo remains a matter of debate. Commonly, Vd2 T cells from healthy individuals are reported to be CD4 -51,53,75,153,154 , ostensibly rendering them impermissible to infection. Surprisingly, however, Wallace et al. 58 reported in 1997 that Vd2 T-cell lines could be productively infected with HIV in vitro over the course of 18 days. Similarly, coinfection with human herpesvirus 6 can induce CD4 expression on cd T cells in vitro, rendering them susceptible to HIV infection. 52 Since then, some studies have reported low-level CD4 expression on peripheral cd T cells ex vivo, 155 which is sufficient to mediate CD4-dependent productive HIV infection. Similarly, humanised mice produce thymic cd T cells that express CD4, CCR5 and CXCR4 and are susceptible to infection by multiple HIV isolates. 156 Perhaps most intriguingly, mucosal Vd2 T cells at the female reproductive tract are reported to be predominately CD4 + . 42 The relevance of Vd2 T-cell infection by HIV was recently highlighted by data indicating that circulating Vd2 cells are a reservoir for replication-competent HIV in ART-suppressed patients. 154 In this study, exposure of Vd2 T cells to IL-2 was sufficient to induce CD4 expression on an average of 15% of isolated Vd2 cells. Three acutely HIV-infected subjects (<23 days postinfection) also exhibited a similar level of CD4 expression on their Vd2 T cells, suggesting that immune activation is sufficient to promote productive infection of Vd2 T cells in vivo. What impact this might have on Vd2-based immunotherapies and latency reactivation-based HIV cure strategies is currently unknown, but should be considered in future studies. 
